Stabilized Immunostimulatory Complex via Electrostatic Peptide Association
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine formulations using synthetic peptide immunogens face challenges such as immunogen degradation, poor adjuvanticity, and stability issues, leading to inadequate immune responses and adverse reactions, particularly with aluminum-based adjuvants and CpG oligonucleotides, which require large doses and have scalability and stability concerns.
Innovation Solution
A stabilized immunostimulatory complex is formed by electrostatic association of cationic peptides with anionic molecules or oligonucleotides, providing self-adjuvanting properties and controlled release, enhancing immune responses while minimizing adverse reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic peptide immunogens are used in vaccine formulations, then safety and regulatory control are improved, but immunogenicity and protective responses are insufficient
Solution Approach 1:
The patent combines synthetic peptide immunogens with CpG oligonucleotides to form a complex that merges the safety advantages of synthetic peptides with the immunostimulatory properties of CpG oligonucleotides, achieving both safety and enhanced immunogenicity
Solution Approach 2:
The invention creates a composite immunostimulatory complex comprising synthetic peptide immunogens and CpG oligonucleotides, where the composite structure provides both the safety profile of synthetic peptides and the strong immunogenic response of CpG-containing complexes
2Object-generated harmful factors
If aluminum-based adjuvants are used to improve immune responses, then adjuvanticity is enhanced, but adverse reactions and scalability issues occur
Solution Approach 1:
The patent changes the chemical parameters of the adjuvant system by replacing aluminum-based adjuvants with CpG oligonucleotides, which have different chemical properties that enable enhanced immunogenicity without the adverse reactions associated with aluminum salts
Solution Approach 2:
The invention uses small-molecule CpG oligonucleotides instead of large aluminum-based adjuvant systems, providing a simpler, more scalable adjuvant that can be easily administered and metabolized
3Object-generated harmful factors
If CpG oligonucleotides are used to enhance immune responses, then adjuvanticity is improved, but large doses and stability concerns are required
Solution Approach 1:
The patent merges synthetic peptide immunogens with CpG oligonucleotides in a 1:1 molar ratio complex, where the combination provides synergistic effects that reduce the required dose of each component compared to using them separately
Solution Approach 2:
The invention changes the dosing parameters by forming a stable complex that reduces the effective dose of CpG oligonucleotides needed, as the complexed form provides more sustained and efficient immunostimulation
4Reliability
If synthetic peptide immunogens are used, then safety is improved, but stability and solubility issues occur
Solution Approach 1:
The patent uses CpG oligonucleotides as an intermediary that forms a complex with synthetic peptide immunogens, where the CpG oligonucleotide acts as a stabilizing agent that improves the solubility and stability of the peptide while maintaining safety
Solution Approach 2:
The invention creates a composite structure where the CpG oligonucleotide component provides stability and solubility enhancement to the synthetic peptide immunogen, forming a stable immunostimulatory complex
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stabilized immunostimulatory complex achieves improved immune responses with reduced dosing and enhanced stability, providing a safe and effective vaccine delivery system that can be scaled up for commercial production.
Implementation Method 1
a stabilized immunostimulatory complex comprising a cationic peptide and an anionic molecule or oligonucleotide or polynucleotide and a method for stabilizing a cationic peptide by complexation with an anionic molecule or oligonucleotide or polynucleotide via electrostatic association
Data Source
AI summary
The present invention provides an immunostimulatory complex specifically adapted to act as adjuvant and as a peptide immunogen stabilizer. The immunostimulatory complex comprises a CpG oligonucleotide and a biologically active peptide immunogen. The immunostimulatory complex is particulate and can efficiently present peptide immunogens to the cells of the immune system to produce an immune response. The immunostimulatory complex may be formulated as a suspension for parenteral administration. The immunostimulatory complex may also be formulated in the form of w/o-emulsions, as a suspension in combination with a mineral salt suspension or with an in-situ gelling polymer for the efficient delivery of an immunogen to the cells of the immune system of a subject following parenteral administration, to produce an immune response which may also be a protective immune response.